Single cell profiling of potentiated phospho-protein networks in cancer cells

被引:546
作者
Irish, JM
Hovland, R
Krutzik, PO
Perez, OD
Bruserud, O
Gjertsen, BT
Nolan, GP [1 ]
机构
[1] Stanford Univ, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol, Stanford, CA 94305 USA
[2] Univ Bergen, Ctr Med Genet & Mol Med, Haukeland Univ Hosp, Bergen, Norway
[3] Univ Bergen, Ctr Med Genet & Mol Med, Proteom Unit, Bergen, Norway
[4] Haukeland Hosp, Haematol Sect, Dept Internal Med, N-5021 Bergen, Norway
[5] Univ Bergen, Inst Med, Haematol Sect, Bergen, Norway
关键词
D O I
10.1016/j.cell.2004.06.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Altered growth factor responses in phospho-protein-driven signaling networks are crucial to cancer cell survival and pathology. Profiles of cancer cell signaling networks might therefore identify mechanisms by which such cells interpret environmental cues for continued growth. Using multiparameter flow cytometry, we monitored phospho-protein responses to environmental cues in acute myeloid leukemia at the single cell level. By exposing cancer cell signaling networks to potentiating inputs, rather than relying upon the basal levels of protein phosphorylation alone, we could discern unique cancer network profiles that correlated with genetics and disease outcome. Strikingly, individual cancers manifested multiple cell subsets with unique network profiles, reflecting cancer heterogeneity at the level of signaling response. The results revealed a dramatic remodeling of signaling networks in cancer cells. Thus, single cell measurements of phospho-protein responses reveal shifts in signaling potential of a phospho-protein network, allowing for categorizing of cell network phenotypes by multidimensional molecular profiles of signaling.
引用
收藏
页码:217 / 228
页数:12
相关论文
共 36 条
  • [31] The role of FLT3 in haematopoietic malignancies
    Stirewalt, DL
    Radich, JP
    [J]. NATURE REVIEWS CANCER, 2003, 3 (09) : 650 - U1
  • [32] Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis
    Thiede, C
    Steudel, C
    Mohr, B
    Schaich, M
    Schäkel, U
    Platzbecker, U
    Wermke, M
    Bornhäuser, M
    Ritter, M
    Neubauer, A
    Ehninger, G
    Illmer, T
    [J]. BLOOD, 2002, 99 (12) : 4326 - 4335
  • [33] Vital statistics
    Tilstone, C
    [J]. NATURE, 2003, 424 (6949) : 610 - 612
  • [34] STAT proteins: novel molecular targets for cancer drug discovery
    Turkson, J
    Jove, R
    [J]. ONCOGENE, 2000, 19 (56) : 6613 - 6626
  • [35] A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial
    Wheatley, K
    Burnett, AK
    Goldstone, AH
    Gray, RG
    Hann, IM
    Harrison, CJ
    Rees, JKH
    Stevens, RF
    Walker, H
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) : 69 - 79
  • [36] Xia Z, 1998, CANCER RES, V58, P3173